A proof-of-concept study of VK2809 in patients with GSD Ia

Trial Profile

A proof-of-concept study of VK2809 in patients with GSD Ia

Planning
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs VK 2809 (Primary)
  • Indications Glycogen storage disease type I
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 13 Sep 2017 New trial record
    • 07 Sep 2017 According to a Viking Therapeutics media release, the company is planning to file an IND later this year for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top